ClinicalTrials.gg
CompletedNCT07927881TBTRANSMISSIONUpdated Nov 10, 2026

Spatiotemporal Modeling of Tuberculosis Transmission Risk in a Clinical Waiting Room Using Environmental and Patient Movement Data: Impact of Simple Patient Management Interventions

An observational study in Tuberculosis (TB), sponsored by Centre for Infectious Disease Research in Zambia. Completed at 1 site in Zambia. Open to participants aged Up to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Centre for Infectious Disease Research in Zambia · Observational

Updated Nov 10, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,000
Ages
Up to 99 Years
Sex
All
01

Study summary

To establish a novel approach for estimating the risk of TB transmission in a healthcare clinic in a high TB/HIV setting in Zambia using data on patient characteristics, indoor CO2 and bioaerosol measurements, and patient flows from video sensors.

Read the detailed description

The proposed study has an observational design, employing exposure assessment methods and implements interventions targeting patient flow. Briefly, we will collect patient-related information (anonymous patient tracking, clinical patient information) and environmental data (CO2 levels, particle concentrations) in Kanyama first level hospital in Lusaka, Zambia, over a period of 6 weeks for approximately 6 hours per day.

02

Conditions studied

  • Tuberculosis (TB)

Browse trials for

Keywords

  • TUBERCULOSIS TRANSMISSION
  • SPATIOTEMPORAL MODELING OF TUBERCULOSIS TRANSMISSION
03

In context

Tuberculosis

1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.

This study's enrollment of 1,000 is above the median of 253 across 317 observational studies indexed under Tuberculosis.

Browse Tuberculosis studies →

Lead sponsor

Centre for Infectious Disease Research in Zambia is the lead sponsor of 41 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

All attending the selected clinics will be included

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All attending the selected clinics will be included

Exclusion criteria

Exclusion Criteria:

  • Clinical study staff members
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,000 participants (actual)
Target follow-up
1 Day
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Patient flow, clustering, occupancy, CO₂, particles, bioaerosols and clinical/epidemiological characteristics.

    Estimated TB transmission risk will be calculated using a spatiotemporal model incorporating environmental conditions and patient movement/occupancy data. The outcome will be summarized as the change in modeled transmission-risk estimates between the pre-intervention and intervention periods.

    Time frame: 6 MONTHS

  2. TB TRANSMISSION

    We aim to establish a novel approach for estimating the risk of TB transmission in a healthcare clinic in a high TB/HIV setting in Zambia using data on patient characteristics, indoor CO₂ and bioaerosol measurements, and patient flows from video sensors. We will use these data to parameterise a novel mathematical model of TB transmission in primary care clinics, identify the drivers of transmission risk, and estimate the impact of interventions targeting patient flows on the risk of TB transmission.

    Time frame: 6 MONTHS

Secondary outcomes

  1. TB TRANSMISSION

    To determine patient flow, patient clustering, and the number of patients at a given time point using anonymous video sensors and environmental data (CO₂ levels, particle concentrations, bioaersol), as well as to study clinical features and to study epidemiological and clinical characteristics of patients seen at the outpatient department, such as TB/HIV suspicion, using clinical information from medical records.

    Time frame: 6 months

07

Study locations

1 site
  • Kanyama First Level Hospital
    Lusaka, Lusaka Province 10101, Zambia
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Aug 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2026
First posted
Nov 10, 2026
StartActual
Mar 18, 2024
Primary completionActual
Aug 17, 2024
CompletionActual
Mar 18, 2025
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07927881
Lead sponsor
Centre for Infectious Disease Research in Zambia
Responsible party
Sponsor
First posted
Nov 10, 2026
Start date
Mar 18, 2024
Primary completion
Aug 17, 2024
Completion
Mar 18, 2025
Last update
Nov 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion